-
Create
account -
Discover profitable
strategies -
Connect exchange
& start earning
Quantitative Strategies & Backtesting results for ABUS
Here are some ABUS trading strategies along with their past performance. You can validate these strategies (and many more) for free on Vestinda across thousands of assets and many years of historical data.
Quantitative Trading Strategy: WMA Crossovers with Volume support on ABUS
The backtesting results for the trading strategy, conducted from November 3, 2022, to November 3, 2023, showcase a profit factor of 0.29. The annualized return on investment (ROI) stands at -16.62%, indicating a negative performance during the given period. On average, the strategy held positions for approximately 1 day and 6 hours. The average number of trades executed per week was 0.49, resulting in a total of 26 closed trades. The winning trades percentage was 30.77%, reflecting a relatively low success rate. However, it should be noted that the strategy outperformed the buy and hold approach, generating excess returns of 14.99%.
ABUS
Choose another period and try again.
Quantitative Trading Strategy: Percentage Price Oscillations with Keltner Channel and Shadows on ABUS
The backtesting results for the trading strategy during the period from November 3, 2022, to November 3, 2023, indicate a profit factor of 0.19. The annualized return on investment stands at -24.05%, showcasing a negative performance. The average holding time for trades was around 4 days and 10 hours, while the average number of trades per week amounted to 0.34. A total of 18 trades were closed during this period. The winning trades percentage was rather low at 22.22%. Despite the negative ROI, the strategy proved to be better than the buy and hold approach, generating excess returns of 5.79%.
ABUS
Choose another period and try again.
Mastering the Golden Cross Strategy for ABUS
- Identify the moving averages to use for the golden cross, typically 50-day and 200-day.
- Plot the moving averages on a stock chart for ABUS.
- Wait for the shorter-term moving average (50-day) to cross above the longer-term moving average (200-day).
- Consider this as a potential bullish signal for ABUS.
- Confirm the golden cross by monitoring the price action and volume of ABUS.
- If the price continues to rise and volume increases, it strengthens the validity of the signal.
- Consider buying ABUS or adding to existing positions based on the golden cross.
- Monitor the price movement and adjust your position accordingly.
Analyzing Golden Cross Timelines for ABUS
When analyzing the Golden Cross, it is important to consider different timeframes. Short-term analysis typically looks at daily or weekly charts, focusing on immediate trends and price movements. Medium-term analysis expands the timeframe to several months, capturing the broader market sentiment and potential shifts in investor behavior. Longer-term analysis encompasses several years, providing a comprehensive understanding of the stock's historical performance and its ability to sustain trends. For ABUS, short-term analysis may track the Golden Cross on a daily basis, while medium and long-term analysis would provide a more extensive overview of the stock's trend strength and potential future movement. As always, combining multiple timeframes can enhance the analysis and provide a well-rounded perspective on the Golden Cross indicator.
Anticipated Hurdles and ABUS Vulnerabilities
Potential Challenges and Risks:
ABUS faces several potential challenges and risks that could impact its future prospects. Firstly, the biopharmaceutical industry is highly competitive, with many companies vying for market share. ABUS may struggle to penetrate the market and gain a competitive edge against well-established players.
Secondly, the clinical development process for new drugs is complex, lengthy, and costly. ABUS must navigate through the various stages of clinical trials, which pose uncertainties and potential setbacks. These trials may not demonstrate the desired efficacy or safety profile, leading to delays and additional expenses.
Moreover, regulatory approval is a significant risk. ABUS must meet stringent regulatory requirements set by the FDA and other authorities. Failure to comply or obtain necessary approvals can hinder the launch and commercialization of its products.
Additionally, ABUS relies heavily on its intellectual property rights to protect its innovations. However, there is always a risk of patent challenges or infringements by competitors, which could impact ABUS’ market exclusivity and revenue potential.
Lastly, the biopharmaceutical industry is subject to rapid technological advancements. ABUS must stay at the forefront of innovation to remain competitive and adapt to changing market trends. Failure to do so could render its technologies obsolete and jeopardize its future growth.
In summary, ABUS faces challenges due to market competition, the complex clinical development process, regulatory approval, intellectual property risks, and technological advancements.
ABUS in a Nutshell
ABUS, or Arbutus Biopharma Corp., is a leading biopharmaceutical company focused on discovering, developing, and commercializing a cure for chronic HBV infection. With a mission to improve patient lives by advancing a cure for HBV, ABUS leverages its deep knowledge in RNA interference (RNAi) and nucleic acid-lipid nanoparticles (N-LNPs) to develop innovative therapies. By targeting the multiple steps of the HBV life cycle, ABUS aims to address the persistent challenges associated with chronic HBV infection. With a robust pipeline of candidates, ABUS is committed to developing safe and effective treatments that could potentially transform the lives of millions affected by this global health burden. With its expertise and advancements in virus-host interactions, ABUS is at the forefront of HBV cure research. As the company continues its efforts in advancing its pipeline, it remains dedicated to improving the quality of life for individuals living with HBV.
Golden Cross: Deceptive Indicators and ABUS Constraints
One of the main limitations of the Golden Cross indicator is the occurrence of false signals. False signals can lead investors to make incorrect trading decisions. This happens when the Golden Cross occurs, but the stock price does not follow the expected upward trend. For example, if a stock like ABUS experiences a Golden Cross but then undergoes a sharp decline, it can leave investors wondering why the indicator failed to predict the reversal. The Golden Cross is not always a foolproof signal and should be used in conjunction with other technical indicators and thorough fundamental analysis to confirm the validity of the signal. Due diligence is important to avoid falling for false signals and potential losses.
Sophisticated backtesting is not only possession of high-esteemed hedge funds anymore.
Impressive Team and support, Backtesting engine with detailed reports, The Strategy builder.
Great purchase!
I have always manually invested in stocks and cryptocurrencies, but after studying Vestinda, I must say it has enormous potential.
Mature platform for trading
Pro: Easy to use, Nice UX, A lot of customization for strategies, Back testing is an awesome tool, can check any strategy in history.
Frequently Asked Questions
During ABUS flash crashes, the performance of the Golden Cross strategy can vary. The Golden Cross refers to a technical analysis indicator in which the 50-day moving average crosses above the 200-day moving average. While it may identify bullish trends, the Golden Cross alone may not shield from flash crashes as these events are often characterized by extreme and rapid price drops. Traders relying solely on the Golden Cross may experience significant losses during flash crashes, highlighting the need for additional risk management strategies and careful observation of market conditions.
To identify a Golden Cross failure and minimize losses in ABUS trading, it is crucial to closely monitor the stock's performance after the Golden Cross formation. If the stock fails to sustain its upward momentum and instead shows signs of weakness, such as a sharp decline in price or a breakdown of key support levels, it may indicate a Golden Cross failure. In this scenario, implementing risk management techniques like setting stop-loss orders, diversifying the portfolio, and closely following news and market trends can help minimize potential losses.
Yes, there can be false signals with the Golden Cross in ABUS trading. The Golden Cross is a bullish technical indicator that occurs when a short-term moving average crosses above a long-term moving average. While this crossover generally signifies a positive trend reversal, it is not foolproof. False signals may arise due to temporary price fluctuations or market volatility, leading to misleading indications. Traders should consider confirming the Golden Cross with other technical analysis tools or indicators to minimize the risk of false signals and make more informed trading decisions.
The Golden Cross is a technical analysis pattern that occurs when a short-term moving average, such as the 50-day moving average, crosses above a long-term moving average, like the 200-day moving average. While the Golden Cross is commonly used in stock trading, its application to ABUS options trading would involve monitoring the price relationship between ABUS stock and the respective moving averages. Traders might interpret a Golden Cross as a bullish signal, indicating a potential upward trend in ABUS stock price, which could then inform their options trading strategy. However, it is important to conduct additional research and analysis before making any trading decisions based on this pattern.
The Golden Cross, a technical analysis indicator, may exhibit less reliability during low liquidity periods for ABUS. In such periods, the limited trading volume can lead to reduced effectiveness of trend-following indicators like the Golden Cross. Low liquidity often results in erratic price movements and increased market noise, making it challenging to accurately identify and interpret signals. Traders should exercise caution and consider incorporating additional factors when assessing the Golden Cross's performance during low liquidity periods for ABUS.
Conclusion
In conclusion, ABUS Golden Cross Trading is a strategy that involves analyzing the EMA golden cross, specifically the EMA 50 200 cross, and monitoring ABUS Golden Cross Trading charts. It can potentially indicate a bullish market trend for Arbutus Biopharma Corp. With its significant developments in the biopharmaceutical sector, investors are looking to capitalize on this strategy to optimize their investment returns. However, it is important to consider different timeframes when analyzing the Golden Cross and to be aware of potential challenges and risks that ABUS faces, such as market competition, clinical development complexities, regulatory approval, intellectual property risks, and technological advancements. Moreover, false signals can occur with the Golden Cross indicator, so it should be used in conjunction with other technical indicators and thorough fundamental analysis.
Successful traders rely on backtesting to be profitable.
Be like them with our
Free Backtesting Guide